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Key points
 Althoughoptogenetics has clearly demonstrated the feasibility of cardiacmanipulation, current
optical stimulation strategies lack the capability to react acutely to ongoing cardiac wave
dynamics.
 Here, we developed an all-optical platform to monitor and control electrical activity in
real-time.
 The methodology was applied to restore normal electrical activity after atrioventricular block
and to manipulate the intraventricular propagation of the electrical wavefront.
 The closed-loop approach was also applied to simulate a re-entrant circuit across the ventricle.
 The development of this innovative optical methodology provides the first proof-of-concept
that a real-time all-optical stimulation can control cardiac rhythm in normal and abnormal
conditions.
Abstract Optogenetics has provided new insights in cardiovascular research, leading to new
methods for cardiac pacing, resynchronization therapy and cardioversion. Although these
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interventions have clearly demonstrated the feasibility of cardiac manipulation, current optical
stimulation strategies do not take into account cardiac wave dynamics in real time. Here, we
developed an all-optical platform complemented by integrated, newly developed software to
monitor and control electrical activity in intact mouse hearts. The system combined a wide-field
mesoscope with a digital projector for optogenetic activation. Cardiac functionality could be
manipulated either in free-runmode with submillisecond temporal resolution or in a closed-loop
fashion: a tailored hardware and software platform allowed real-time intervention capable of
reacting within 2 ms. The methodology was applied to restore normal electrical activity after
atrioventricular block, by triggering the ventricle in response to optically mapped atrial activity
with appropriate timing. Real-time intraventricular manipulation of the propagating electrical
wavefront was also demonstrated, opening the prospect for real-time resynchronization therapy
and cardiac defibrillation. Furthermore, the closed-loop approach was applied to simulate a
re-entrant circuit across the ventricle demonstrating the capability of our system to manipulate
heart conduction with high versatility even in arrhythmogenic conditions. The development of
this innovative optical methodology provides the first proof-of-concept that a real-time optically
based stimulation can control cardiac rhythm in normal and abnormal conditions, promising a
new approach for the investigation of the (patho)physiology of the heart.
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Introduction
Closed-loop stimulation is an experimental paradigm that
enables new research and therapeutic targets byperturbing
living tissue based on physiological parameters acquired
in real time. In contrast to open-loop experiments,
which rely on the application of predetermined stimuli,
closed-loop experiments dynamically respond to living
tissue, providing new insights into how these systems
are controlled in vivo. Current applications in the
cardiovascular sciences include dynamic clamp protocols
which control electrophysiological properties in real time
(Wilders, 2006; Altomare et al. 2015), the application
of variably timed stimuli to control arrhythmias in
intact tissue (Christini & Collins, 1996; Christini et al.
2006; Ploux et al. 2014), and protocols that create
closed conduction circuits of variable length to explore
the dynamics of cardiac re-entry (Frame & Simson,
1988). Arrhythmia control strategies have first been
demonstrated using microelectrodes for sensing and
stimulating tissue, but these low-resolution systems have
a limited ability to respond to complex, spatially variable
activity in cardiac tissue. More recently, researchers
have investigated the use of optically captured signals
to detect wave activity, which are then used to drive
a stimulating electrode (Iravanian & Christini, 2007;
Kulkarni&Tolkacheva, 2015).These approaches, however,
cannot replicate the effect of a dynamically changingwave-
front of conduction as the electrode is static. The emerging
field of cardiac optogenetics offers a potential solution to
this experimental problem.
Since its first application in cardiac sciences to map
the origin of the cardiac pacemaker activity and pre-
cisely trigger the pacing rhythm in 2010 (Arrenberg et al.
2010; Bruegmann et al. 2010), optogenetic methods have
been used for in vitro and in vivo research, ranging
from single molecule studies to anti-arrhythmic studies
in the intact heart. A number of original studies and
reviews have tried to validate optogenetics as a tool for
clinical human applications (Ambrosi & Entcheva, 2014;
Ambrosi et al. 2014; Vogt et al. 2015), while in silico
simulations have established limitations and requirements
for such a purpose (Boyle et al. 2013, 2015; Karathanos
et al. 2016). The first therapeutic approach based on
optogenetics was demonstrated in 2015 (Nussinovitch
& Gepstein, 2015), where optogenetic resynchronization
was performed employing a fibre-optics-based multi-site
illumination of a rat heart in which viral vectors were
used for infection to expressChannelrhodopsin-2 (ChR2).
Recently, three independent groups (Bruegmann et al.
2016; Nyns et al. 2016; Crocini et al. 2016a) have
demonstrated one of the more expected therapeutic
applicationsofChR2:optical defibrillation. In this context,
Crocini et al. 2016a explored new strategies of optical
defibrillation using a patterned ChR2 stimulation based
on previously acquired knowledge from optical mapping
recordings. This approach limits the applicability of
the optical manipulation within stationary dynamics.
The possibility of optical manipulation of the electrical
conduction based on ongoing cardiac dynamics may
represent a new approach for the investigation of the
physiology of the heart, opening promising perspectives
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for the clinical development of aminimally invasive optical
pacemaker and novel resynchronization-therapy devices.
Recently, a high-resolution, all-optical approach has
been developed to achieve parallel optical control of
cardiac excitation waves (Burton et al. 2015; Entcheva
& Bub, 2016; Feola et al. 2017). Here, we closed the
loop of truly parallel optical manipulation of cardiac
activity by demonstrating an all-optical, closed-loop
system comprising a high-speed sCMOS camera as
sensor combined with a digital micromirror device
(DMD)-based projector as the actuator. We controlled
cardiacdynamics in geneticallymodifiedChR2-expressing
mice by projecting user-defined patterns at precise times
on the myocardium based on detected cardiac activity.
The system allowed real-time intervention within 2 ms of
detected activity, enabling tailored, tuneablemodifications
of cardiac dynamics.
Methods
Ethical approval
All animal handling and procedures were performed in
accordancewith the guidelines fromDirective 2010/63/EU
of the European Parliament on the protection of animals
used for scientific purposes and conformed to the
principles and regulations as described in the editorial by
Grundy (2015). The experimental protocol was approved
by the Italian Ministry of Health (protocol number
647/2015-PR).
Mouse model generation
As previously described (Zaglia et al. 2015; Crocini
et al. 2016a), adult mice with a genetic back-
ground C57B6J and expressing cre-recombinase
under the control of the α-MyHC promoter with
B6.Cg-Gt(ROSA)26Sortm27.1(CAG-COP4∗H134R/td
Tomato)Hze/J (Charles River, Wilmington, MA,
USA) were bred and the resulting offspring had the
STOP cassette deleted in their heart, resulting in
cardiac expression (α-MyHC-promotor driven) of the
hChR2(H134R)-tdTomato fusion protein.
Isolated and perfused mouse heart
Transgenic mice were heparinized (5000 units mL−1) and
anaesthetized by inhaled isoflurane (5%). The excised
heart was immediately bathed in Krebs–Henseleit (KH)
solution and cannulated through the aorta. The KH
buffer contained (in mM): 120 NaCl, 5 KCl, 2 Mg2SO4,
1.8 CaCl2, 20 NaHCO3, 1.2 NH2PO4 and 10 glucose, then
equilibrated with carbogen (95% O2 5% CO2), pH 7.4.
Contraction was inhibited with blebbistatin (5 μM) in
the solution. The cannulated heart was retrogradely
perfused (Langendorff perfusion) with the KH solution
at 2–5 mL min−1 and then transferred to a custom-built
optical mapping chamber at a constant flow. Experiments
were performed at 37°C with the exception of those
relating to Figs 3 and 5 where, to reduce the conduction
velocity, a temperature of 22°C was set. Two platinum
electrodes were placed under the heart to monitor
electrical activity via an electrocardiogram (ECG). After
stabilization of the electrocardiogram frequency after
a few minutes, 1 mL of perfusion solution containing
the voltage-sensitive dye (VSD; di-4-ANBDQPQ,
50 μg mL−1, University of Connecticut Health Center,
Farmington, CT, USA) (Matiukas et al. 2007) was bolus
injected into the aorta.
Cell isolation and patch clamp recording
Ventricular cardiomyocytes from ChR2 transgenic mice
were isolatedby enzymatic dissociationasdescribedbefore
(Sacconi et al. 2012; Crocini et al. 2014b, 2016b; Scardigli
et al. 2017). Briefly, animals are heparinized (5000 U kg−1,
I.P.) and deeply anaesthetized with isoflurane. After
excision, the heart was immediately bathed in cell iso-
lation buffer and the proximal aorta was cannulated for
perfusion in Langendorffmode. Buffer solution contained
(inmM): 113NaCl, 4.7KCl, 0.6KH2PO, 0.6Na2HPO4, 1.2
MgSO4, 12 NaHCO3, 10 KHCO3, 10 Hepes, 30 taurine,
10 glucose and 10 2,3-butanedionemonoxime, pH 7.3
(adjustedwithNaOH).Afterperfusionat 37°Cfor3–4min
with a constant flow of 7–8 mL min−1, the solution
was switched to a recirculating enzyme solution, made
from the same buffer with supplemented 0.1 mg mL−1
LiberaseTM (RocheAppliedSciences, Penzberg,Germany).
After 7 min, the ventricles were excised and cut into small
pieces in buffer solution supplemented with 1 mg mL−1
BSA. Gentle stirring facilitated further dissociation of
myocytes. The cell suspension was left to settle and the
cell pellet was resuspended in Tyrode buffer (in mM):
133 NaCl, 4.8 KCl, 1.2 MgCl2, 0.6 CaCl2, 10 glucose and
10 Hepes, pH 7.35 (adjusted with NaOH). Patch-clamp
studies were performed as previously described (Coppini
et al. 2017). For resting membrane potential and action
potential recordings, the pipette solution contained (in
mM): 115 potassiummethanesulfonate, 25 KCl, 10Hepes,
3 MgCl2. Action potentials were elicited with short (3 ms)
blue light pulses (470 nm) at a stimulation frequency of
2 Hz.
Optical imaging and real-time manipulation platform
Optical mapping and control were performed using
a custom-made mesoscope. The whole mouse heart
was illuminated in wide-field configuration using a ×2
objective (TL2x-SAP, Thorlabs, Newton, NJ, USA) and
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a light emitting diode (LED) operating at a wavelength
centred at 625 nm (M625L3, Thorlabs) followed by a
band-pass filter at 640/40 nm (FF01-640/40-25, Semrock,
Rochester, NY, USA). The heart was illuminated with
a maximum intensity of 1 mW mm−2. A dichroic
beam splitter (FF685-Di02-25 × 36, Semrock) followed
by a band-pass filter at 775/140 nm (FF01-775/140-25,
Semrock) was used for collecting the VSD-emitted
fluorescence. Notably, the tdTomato fusion protein
co-expressed with ChR2 was not excited at this excitation
wavelength. A ×20 objective (LD Plan-Neofluar ×20/0.4
M27, Carl Zeiss Microscopy, Oberkochen, Germany)
was used to focus the fluorescence in a central portion
(128 × 128 pixels) of the sensor of a sCMOS camera
(OrcaFLASH 4.0, Hamamatsu Photonics, Shizuoka,
Japan) operating at a frame rate of 1.6 kHz (630 μs
actual exposure time). To manipulate electrical activity,
a Texas Instruments Lightcrafter 4500 projector (Dallas,
TX, USA), which contains a digital micro-mirror
device (DMD), and three high-powered LEDs, enabled
projection of user-defined light patterns onto the heart.
The projector is optically integrated with the mesoscope
using a high numerical aperture (NA; 0.1) relay system
providing a high coupling efficiency of the order of
30%. Importantly, the Lightcrafter’s LEDs were driven
by an external driver (LM3433-1 LED Driver Evaluation
Board, Texas Instruments) to achieve higher light
intensities. Both green and blue emission were exploited
in our experiments, using a second dichroic beam
splitter (FF484-FDi0136, Semrock) for the ChR2 spectral
activation range. All microscope components were fixed
onto a custom vertical honeycomb steel breadboard. See
the Appendix describing exhaustively all necessary optical,
mechanical and electronical specification and details to
reproduce the system.
Data analysis
F/F0 imaging of electrical activity was performed using
ImageJ: for each frame, the mean baseline was first sub-
tracted and then the frame was normalized to the mean
baseline yielding a percentage change in fluorescence over
time. Since the blue light employed for ChR2 stimulation
could affect recorded traces by exciting the VSD, where
appropriate, the single frame containing a locally confined
stimulation artifact was removed during post-processing.
The activation maps were generated by performing a
threshold operation (pixel intensity>50%maximum) on
the cross-correlation data sets and replacing the active
pixels with a time stamp. Sequential frames were collapsed
into one frame where each pixel corresponds to the time
delay of activation with respect to a user-defined start
time. Isochronal lines are found using a marching squares
algorithm, and colour coded using a blue lookup table. For
patch clamp experiments, the electrical data were analysed
usingpCLAMP(MolecularDevices, Sunnyvale,CA,USA).
Statistics
To demonstrate the robustness of the presented method,
three hearts were used for each experimental category
(Figs 3–5). The robustness was validated by the stability
of the closed-loop in tens of trials and the reproducibility
of the imposed real-time manipulation (5–10 trials per
heart per experiment). Data are expressed as means ±
SEM. Patch clamp experiments (Fig. 1C and Supporting
information Fig. S1) were performed using six cells of two
mice. Analysis of variance (ANOVA) was used between
the four experimental classes (OFF1, 2 mW mm−2,
40 mWmm−2, OFF2). Dose–response curve experiments
(Supporting information Fig. S2) were performed using
six mice. In this experiment, the activation trials were
analysed using binomial distribution statistics where the
Wilson score interval was applied.
Results
A wide-field mesoscope (Fig. 1A) operating at 1.6 kHz
was used to map the action potential propagation in
Langendorff horizontally perfused mouse hearts stained
with a red-shifted VSD (di-4-ANBDQPQ; Matiukas et al.
2007). The platform, implemented with a DMD-based
light crafter, enabled projection of user-defined light
patterns onto the heart. We used transgenic mice
expressing the photosensitive ion channel ChR2 in
the myocardium under the control of the α-MyHC
promoter and exploited light-induced depolarization
to manipulate local electrical functionality (Fig. 1B).
Notably, the use of a VSD excitation wavelength of
640 nm completely avoided ChR2 excitation (excitation
peak at 470 nm) allowing patterned optogenetics
stimulation during optical mapping. Specifically, using
patch-clamp experiments on isolated ChR2-expressing
cardiomyocytes, we found that during red light
illumination (even applying 40 times stronger intensity
than necessary for imaging) there was no significant
variation of resting membrane potential (Fig. 1C) and
action potential amplitude or duration (Supporting
information, Fig. S1).
The response of the heart to different ChR2 patterns
in terms of illumination intensity and pulse duration
(dose–response curves) was characterized (Supporting
information Fig. S2). We found that the platform
allowed elicitation of action potential even with a very
small excitation area, opening the possibility of pattern
stimulation at high spatial resolution.
The system allowed two operating modalities: a
loop-off mode (i.e. free-run optical mapping with the
C© 2018 The Authors The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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capability to illuminate at predefined intervals without
active control) with a temporal resolution of 630 μs,
producing 16-bit images (Fig. 2A, blue cycle), and a
loop-on mode (closed-loop), with a temporal resolution
of 2 ms, producing 8-bit images. In loop-on mode
(Fig. 2A, green cycles), while HC Imaging software
(Hamamatsu Photonics) acquired and saved images in
time-lapse modality in a solid-state disk (SSD) at 500 Hz,
custom-made LabVIEW software performed real-time
image analysis of the saved images. The fluorescence
signal from either a single region of interest (ROI) or
else the ratio from two distinct ROIs was calculated at
every cycle and the last obtained value was compared
with the already processed ones: when the current
value overcame a set threshold, the software activated
the DMD stimulation with an imposed temporal delay
and illumination exposure. Even though computationally
more intensive, the ratiometric approach can be used in
photobleaching-sensitive experiments. The performance
of the imaging set-up in both loop-off and loop-on
modes was evaluated during sinus rhythm in Langendorff
perfused hearts: Fig. 2B shows cardiac electrical action
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Figure 1. Targeted optogenetic manipulation of cardiac conduction
A, scheme of the wide-field fluorescence mesoscope. A red LED followed by a band-pass filter (640/40 nm) excites
through a ×2 objective the whole mouse heart, stained with a red-shifted electro-chromic voltage-sensitive dye
(Di-4-ANBDQPQ). A dichroic beam splitter followed by a band-pass filter (775/140 nm) is used for collecting the
emitted fluorescence signal. A 4f system is adopted to collimate the beam onto a ×20 objective. The signal is then
focused into a central portion (128 × 128 pixels) of a sCMOS sensor operating at a frame rate of 1.6 kHz (630 μs
actual exposure time). A commercial light steering solution based on a digital micro-mirror device (DMD) was
coupled with the mesoscope using a high numerical aperture relay system and a dichroic beam splitter. B, optical
mapping during four patterns of optogenetic stimulation: single-point, whole ventricle, vertical line and horizontal
line, designed as reported by the blue traits on the fluorescence image (F0) of the heart. Six representative frames
of optical mapping (F/F0) showing the electrical activation in red and the baseline in cyan. All stimulations were
performed with a light intensity on the sample of 4 mW mm−2 and 2 ms exposure time. Scale bar: 2 mm. C,
on the left, a representative trace of membrane potential recorded in cardiomyocytes isolated from ChR2 heart
using patch clamp. At the beginning of the recording (OFF1), the optogenetic excitability of the cell was confirmed
inducing sixteen action potentials using blue light pulses (blue lines). In the remainder of the recording, the red
LED used for VSD imaging was turned on with two different power intensities (2 mW mm−2, thin red line and
40 mWmm−2, thick red line) and turned off again (OFF2) showing no variation in resting membrane potential. On
the right, graph shows resting membrane potential during different states of red LED illumination. Each data point
(black circle) represents the average of membrane resting potential of a different cell. Also indicated is the mean
and the standard error of the mean of each illumination state. No statistically significant differences (ANOVA;
number of mice, 2; number of cells, 6) were found between categories.
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potential propagation,which could be resolved temporally
and spatially even in the lower-resolution loop-on
modality.
First, we validated real-time cardiac intervention in
paced (control) conditions. Electrical (ECG) and optical
recordings were used to monitor spontaneous activity.
Using a bipolar electrode, a burst of electrical stimuli
(3 ms in duration at 5 Hz) was delivered to the heart apex
(yellow arrow in Fig. 3A) to overdrive the sinus rhythm.
Without optical stimulation, VSD mapping of electrically
stimulated activity demonstrated uniform propagation
from the apex to the surrounding myocardium (Fig. 3B,
top row). Using the ratiometric approach, two ROIs were
selected near the apex as shown in Fig. 3A (green and
red rectangles). When their ratio crossed the threshold,
the projector illuminated the ventricles with a large
circular pattern (Fig. 3B, bottom row). Considering a
typical shot noise at rest within our ROI (typically of
an area of 200–600 pixels) of 0.2–0.02% of F/F0 and
VSD sensitivity of 4% (see Supporting information
Fig. S3), a threshold of 1% of F/F0 was selected. The
electrical stimulus generated a wave that initially (0–2ms)
propagated following the same kinetics shown in loop-off
mode but, as shown in the frame acquired at 6 ms,
the optogenetic manipulation immediately activated the
whole ventricle anticipating the electrical propagation.On
average, experiments performed in three different hearts
(total number of trials = 21) displayed a whole ventricle
activation time of 27.8 ± 0.7 ms in loop-off mode versus
4.7 ± 0.3 ms during closed-loop optical manipulations.
We then evaluated the system’s ability to control
ventricular activation time after detection of atrial activity.
The system was first applied to manipulate the atrio-
ventricular (AV) node delay that under sinus rhythm was
found to be of the order of 70 ms (Fig. 4A). In this
experiment, the two ROIs were positioned on the atria
(Fig. 4B, green circle) and ventricle (Fig. 4B, red circle),
and the stimulation threshold was set to 1% of F/F0.
The anticipation of the ventricle activation was performed
imposing a user-defined delay of 0, 10 and 20 ms between
the trigger and the DMD stimulation (Fig. 4B and
Supporting information Fig. S4). The ventricle activation
was induced projecting a localized spot at the apex or
a wide circle of light (Fig. 4B, blue areas). A similar
approach was also used to restore timely ventricular
activation after an AV block. Here, we experimentally
induced AV block by adding 50 μL of ethanol to the
perfusing solution, which resulted in a progressive loss
High speed at 1.6 kHz at 16 bit (loop off)
500 Hz LabVIEW loop
Camera Link CPU based
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140 ms70 ms62 ms18 ms6 ms0 ms −0.04
0
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Figure 2. Real-time optical intervention
A, schematic workflow of the hardware and software architecture. A sCMOS camera, connected through two
camera links to the workstation, saves the data in a RAID array of solid-state disks (SSD). The camera can run
either in high-speed (blue cycle) or time-lapse modality for closed-loop operation (green cycle). During the latter,
custom-written LabVIEW software performs a real-time analysis on images as they are saved on the SSD (green
cycle): a previously acquired image of the heart is used as reference to select two ROIs, whose mean values are
compared every 2 ms. When the ratio between the two ROIs exceeds the absolute value of a set threshold (Thr),
optogenetic stimulation is activated, with user-defined temporal delay and intensity. B, optical mapping during
sinus rhythmwith the twomodalities: in loop-off at a frame rate of 1.6 kHz (16-bit images) and in loop-on modality
operating at 0.5 kHz (8-bit images). The fluorescence signal (F/F0) of two ROIs selected on atrium and ventricle
(green and red circle respectively, reported on the fluorescence baseline image) are shown for both acquisition
modalities. Scale bar: 2 mm.
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of coordinated activity between the atria and ventricles.
We monitored live ECG recordings to confirm complete
AV block before starting optical stimulation (Fig. 4C).
VSD mapping clearly showed no ventricular activation
after atrial activity (Fig. 4D, top row). The system then
projected a localized spot (Fig. 4D, middle row) or wide
circle of light (Fig. 4D, bottom row) on the ventricle
after user-defined delays of 50 ms after detection of
atrial activity. Repeated experiments performed in three
different hearts (total number of trials = 16) showed
ROI
ROI
A
B
20 ms
1%
−0.04
0
OFF
ON
0 ms 2 ms 6 ms 10 ms 14 ms 18 ms 22 ms 26 ms 46 ms
ΔF/F0
Figure 3. Intra-ventricular manipulation
A, a slowing down of the ventricular action potential propagation was induced by applying an electrical stimulation
on the apex of the ventricle (yellow lightning). Two reference ROIs were selected (red and green rectangles) and the
ROI ratio was obtained, with a 1% threshold and with no delay in activation. ChR2 stimulation was achieved with
a light intensity of 4 mWmm−2 and 2 ms exposure time (blue arrowhead). B, the wave-front propagation without
the real-time intervention (OFF) and with the optogenetic activation (ON). Frames acquired after photo-stimulation
(blue arrowhead) clearly show the differences in wave-front propagation, highlighting the acceleration of ventricle
activation. Scale bar: 2 mm.
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Figure 4. Optical manipulation of atrioventricular delay
A, optical mapping of spontaneous heart activity, with typical atrioventricular (AV) temporal delay around 70 ms.
B, the optical system was used to reduce AV delay by triggering the optical stimulation of the ventricle according
to optically mapped atrial activity. The two reference ROIs (red and green circles) are positioned on atrium and
ventricle respectively (1% threshold). As first stimulation pattern, a single point (blue area) was applied on the
ventricle with three different temporal delays: 0, 10 and 20 ms after atrium activation. The underlined time frames
highlight different delays. In the last row, whole-ventricle activation was performed with a temporal delay of 0 ms.
ChR2 stimulation was achieved with a light intensity of 4 mW mm−2 and 2 ms exposure time. White arrowheads
indicate atrial activation. Scale bar: 2 mm. C, a stationary AV block was established by adding ethanol to the
perfusion solution. ECG clearly demonstrates the presence of an AV block, since the P wave is not followed by
a proper QRS complex. D, after inducing an AV block, the OFF modality shows no ventricular activation after
atrial triggering. A real-time intervention (ON) was performed using single-point and wide-area illumination, with
50 ms delay (1% threshold, light intensity of 4 mW mm−2 and 2 ms exposure time). Photo-activation results in AV
resynchronization, restoring normal cardiac conduction patterns during sinus rhythm. White arrowheads indicate
atrial activation. Scale bar: 2 mm.
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a 100% successful capture of optogenetic ventricular
activation following AV block for different stimulation
patterns. These proofs of principle clearly demonstrate the
ability of our methodology to manipulate the onset and
the propagation properties of the action potential across
the ventricle and AV resynchronization after block.
As a final example, the system was used to mimic a
pathological condition by simulating a re-entrant circuit
in a healthy heart. The system initiated with the detection
of spontaneous activity (marked with a red asterisk in
Fig. 5) within a continuouslymonitored ROI placed in the
base of the ventricle. Once detected, the system applied an
optogenetic trigger to generate an action potential at the
apex of the heart. The action potential then propagated
toward the base and once a variation in VSD fluorescence
intensity was again detected within the ROI, the cycle was
re-started by activation of a new action potential in the
apex (Fig. 5). As shown in Fig. 5A, we were able to obtain
a stable re-entrant circuit when an activity detected at the
base was reinjected at the apex with an imposed time delay
of 200 ms. However, when reducing this delay to 150 ms
(Fig. 5B), the re-entrant circuit became unstable, probably
due to a subsequent optical stimulus occasionally falling
within the refractory phase of the apex. Since in such a
case the action potential in the apex failed to propagate
to the base, no variation in fluorescence intensity was
detected by the system and, consequently, no new optical
stimulus was delivered to the apex, effectively inter-
rupting the re-entrant circuit. In such cases, a spontaneous
action potential was required to re-start the close-loop
manipulation. On average, experiments performed in
three different hearts (total number of trials = 30)
displayed stable re-entrant circuits (within a recording
time of 16 s) with delays of 200–250 ms while delays of
150–200 ms produced shorter re-entrant circuits with a
lifetime of 6.2 ± 1.9 s. This example demonstrates the
capability of the all-optical platform to simulate re-entrant
circuits in mouse hearts with ease and, more generally, to
precisely control its cycle length on demand.
Discussion
In this work, advances in optogenetics and optics were
exploited to implement a wide-field mesoscope that could
map and control the electrical activity of intact mouse
hearts in real-time. The system was characterized in terms
of specificity and spatio-temporal resolution. Custom
control software was developed and its ability to operate in
closed-loop control mode with a sub-2 ms response time
was validated in intact ChR2-expressing mouse hearts, in
both healthy and pathological conditions. In the present
work, we firstly provided all necessary technical details to
reproduce the platform and, secondly, we demonstrated
all-optical closed-loop control in three different proofs of
principle: (i) manipulation of intraventricular electrical
activation, (ii) manipulation of AV conduction, and (iii)
induction of re-entrant circuits.
Looking forward, dynamic control of ventricular
excitation waves can have a large impact on the
study and treatment of arrhythmias. We have pre-
viously demonstrated that low-energy mechanistically
based ChR2 stimulation patterns can efficiently terminate
cardiac arrhythmias (Crocini et al. 2016a), but since that
system was not capable of operating in real-time, cardio-
version depended on the inter-experiment regularity
of arrhythmias in our mouse model. In contrast,
the closed-loop control platform presented here could
differentially stimulate the tissue based on the timing and
route taken by each re-entrant circuit. Such a capability
A
B
40 ms
0
40 ms
0
= 200 ms
= 150 ms
2 s
2 %
*
* * *
Figure 5. Optically induced re-entrant circuit
Left, fluorescence image of the heart. Re-entrant circuit was started by detection of spontaneous ventricular activity
at the base of the heart (green ROI). After detection, ChR2 stimulation at ventricle apex (blue circle) was applied
after a delay of 200 ms (A) or 150 ms (B) concluding one loop-of the cycle. Scale bar: 2 mm. Centre, corresponding
colour-scaled isochronal map reporting the activation time per pixel. Right, fluorescence signal (F/F0) extracted
from the green ROI. The stable re-entrant circuit at a stimulus delay of 200 ms (A) becomes unstable at a delay of
150 ms (B) showing discontinuity in the action potential time interval. Spontaneous action potentials (red asterisks)
detected in the green ROI are needed in this case to re-start the re-entrant cycle.
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is essential for the study of the minimum requirements
for successful defibrillation in larger animals. Compared
to the mouse model system used here, larger animals
may tend to display more complex arrhythmias due to
their increased ventricular surface area (Garrey, 1914;
Winfree, 1994; Vaidya et al. 1999), and these may best be
cardioverted using simultaneous multi-site stimulation.
Multi-site optogenetic stimulation is also essential to
explore strategies for real-time resynchronization therapy
(Nussinovitch & Gepstein, 2015). In these cases, the
real-time algorithms must be capable of detecting the
wave-front shape and propagation direction and, based on
that, design a tailored stimulation pattern. Furthermore,
especially for real-time resynchronization, a closed-loop
frequency of 500 Hz is probably not sufficient. Currently,
the maximal closed-loop frequency was imposed by
the frame rate achievable with our camera. Future
developments in sCMOS technology, data transfer and
storage will likely improve the achievable frame rate.
Furthermore, the system could be implemented with a
field-programmable gate array (FPGA) video acquisition
card capable of significantly improving reaction time by
performing image processing on board.
Methods for real-time manipulation of excitation
waves could be leveraged to develop alternative
approaches to study action potential alternans (Merchant
& Armoundas, 2012). Action potential alternans are
defined as beat-to-beat alterations of action potential
duration and can occur in either healthy or diseased
hearts. Action potential alternans are classified as
concordant, when action potential duration shortens
or prolongs simultaneously in all cells, or discordant,
when neighbouring cells display alternans in opposite
phases. Although the cellular mechanisms are not fully
elucidated, discordant alternans are known to increase
predisposition to arrhythmogenesis in diseased hearts
(Ng et al. 2007; Narayan et al. 2008). The possibility to
manipulate the action potential duration optically (Park
et al. 2014) combined with our optical system could allow
a detailed investigation of the level of spatial and temporal
discordance required for the onset of an arrhythmic
event, as well as assess strategies to control alternans
that go beyond current methods, which rely on a single
stimulating electrode.
In the present work, we demonstrated the capability
of the system in modulating AV delay and treating
AV block by monitoring atrial electrical activity. Our
system could be employed to investigate rate-adaptive
AV delay modulation. For instance, administration of
a β-adrenergic agonist would increase the heart rate
and thus change the optimal AV delay. By using heart
rate modulators, our optical platform could be used to
optimize AV delay in a variety of conduction disorders.
ChR2 expression could be achieved in transgenic models
of heart block, brady-cardiomyopathy or arrhythmia
(Fabritz et al. 2004; Milan & MacRae, 2005; Baruscotti
et al. 2011) by means of viral transduction (Vogt et al.
2015). The closed-loop control capability of our platform
enabled dynamic responses to changing activity, allowing
assessment of real-time intervention strategies.
While in the first two examples the platform essentially
represented a work bench on which various intervention
protocols were tested to correct electrical abnormalities,
in the third example, the real-time approach was used
to impose a customizable electrical dysfunction. In this
case, the possibility to create and control the properties of
re-entrant circuits represents an important achievement
that will supply not only basic mechanical insights of
this electrical dysfunction but also a reliable model for
pharmacological screening.
Functional light-based technologies for actuation
and detection (Crocini et al. 2014a, 2017) that
provide fundamental insights in cardiac pathophysiology
are now proven. The development of an all-optical
control platform provided the first proof-of-concept
demonstration that optogenetics can be used to
dynamically control complex cardiac rhythms based on
real-time detection of excitation waves, opening new
research directions for studying cardiac pathophysiology.
Appendix
All optical, mechanical and electronic details necessary to
reproduce the methodology are listed here.
Optical set-up
A LED (M625L3, Thorlabs, Newton, NJ, USA;
625 nm centre wavelength, 18 nm full width at
half-maximum (FWHM) bandwidth) is collimated
(C, ACL2520U-A, Thorlabs), bandpass-filtered (F1,
FF01-640/40-25 Semrock, Rochester, NY, USA) and
focused by a lens (L1, f = 100 mm) to generate Ko¨hler
illumination at the sample objective (O1, TL2x-SAP,
Thorlabs, ×2, 0.1 NA) (Fig. A1; see Table A1 for a
complete list of optical components). A dichroic mirror
(DC1, FF685-Di02-25x36, Semrock) is used to inject the
excitation light (red). The fluorescence (green) emitted by
the red-shifted, electro-chromic VSD (Di-4-ANBDQPQ)
is bandpass-filtered (F2, FF01-775/140-25, Semrock)
and re-imaged with two 4f-lens systems (F2, F3, both
f = 150 mm) onto the back focal plane of the
camera objective (O2, LD Plan-Neofluar ×20, 0.4 NA,
Carl Zeiss Microscopy, Oberkochen, Germany) which
creates an image directly onto the chip of a sCMOS
camera (OrcaFlash4.0, Hamamatsu, Shizuoka, Japan).
The objective has a longworking distance (WD)of 7.9mm
(at coverglass of 0.75 mm thickness) which matches the
geometrical constraints to reach the chip of the camera
embedded in a vacuumprotected by a coverglass (see inset
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Fig. A1). Only a central portion (128 × 128 pixels) of the
sensor is used and allows operation at an increased frame
rate of 1.6 kHz corresponding to an actual exposure time
of 630 μs.
Optogenetic activation (blue) was implemented
through a commercially available lightcrafter
(DLPLCR4500EVM, Texas Instruments, Dallas, TX,
USA) comprising a light engine including RGB LEDs
and a 912 × 1140 diamond pixel 0.45 inch WXGA
digital micro-mirror device (DMD). DMD functional
principles and specifications are detailed in Fig. 3, while
changes made to the lightcrafter to adapt it to its use for
optogenetic activation are described in detail in Fig. A4.
The primary image projected by the lightcrafter was
made to coincide with the detection field of view of a
third objective (O3, TL2x-SAP, Thorlabs, ×2, 0.1 NA)
and reimaged onto the sample by means of two 4f-lens
systems (F2, F3, both f = 100 mm). The light used for
ChR2 activation was injected into the beam path with a
second dichroic mirror (DC2, FF484-FDi0136, Semrock).
Specifications of the mesoscope
Considering the temporal resolution required to follow
action potential propagation (1 ms) and the minimum
sampling frequency necessary according to the Nyquist
theorem, the mesoscope needs to operate at a frame rate
of around 2 kHz corresponding to a frame exposure
time of 500 μs. The maximum number of pixel lines
the OrcaFlash4.0 sCMOS camera can support in free-run
mode at this approximate frame rate is 128 lines at 1.6 kHz
when using camera link. Taking into account a typical
mouse heart of approximately 10 mm × 10 mm, the
total magnification of the mesoscope has to be 0.0825
where 1 pixel on the camera (6.5 μm) corresponds to
approximately 80μmin themouseheart andconsequently
128 pixels × 128 pixels corresponds to a field of view
of approximately 10 mm × 10 mm in the sample
plane.
The above considerations on magnification
requirements set the focal lengths of both tube
lenses used in the two 4f-systems (Fig. A2) and therefore
lead to a mismatch of beam diameters; the clear aperture
at the back focal plane of the camera objective (BFP2 =
6.6 mm) imposes a limit to the effective beam diameter
at the sample objective and therefore a reduction of its
nominal to an effective NA (NAeff) of 0.033. Using this
effective NA, the optical resolution of the two 4f-lens
systems in terms of the FWHM of its point spread
function (PSF) is 0.61 × λ × M/NAeff = 0.8 μm when
using light of λ = 500 nm and an optical magnification
M = 0.0825.
In closed-loop mode, 8-bit images are saved to a
solid-state disk (SSD) at 500 Hz where a custom-made
LabVIEW program (National Instruments, Austin, TX,
USA) performs a real-time image analysis. While images
could also be buffered and processed in the workstation’s
random access memory (RAM) to increase the 2 ms
temporal resolution, saving to the SSD allows us to
use proprietary Hamamatsu software for time lapse
acquisition and a simple LabVIEW program for real time
analysis.
Figure A1. Custom mesoscope
C, collimation lens; DC, dichroic mirror; DMD, digital micro-mirror device; F, filter; L, lens; LED, light emitting
diode; M, mirror; O, objective; sCMOS, scientific complementary metal-oxide semiconductor camera; WD, working
distance.
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Table A1. Optical components
Component Manufacturer Part no. Specifications
Collimator Thorlabs, Newton,
NJ, USA
ACL2520U-A C Aspheric condenser lens, φ 25 mm, f = 20.1 mm, NA = 0.60,
ARC: 350–700 nm
Elliptical mirror Thorlabs BBE1-E02 M1 1′′ broadband dielectric elliptical mirror, 400–700 nm
Thorlabs BBE1-E03 M2 1′′ broadband dielectric elliptical mirror, 750–1100 nm
Lenses Thorlabs AC254-100-A-ML L1 f = 100 mm, φ 1′′ achromatic doublet, ARC: 400–700 nm
Thorlabs AC254-150-B-ML L2 f = 150 mm, φ 1′′ achromatic doublet, ARC: 650–1050 nm
Thorlabs AC254-150-B-ML L3 f = 150 mm, φ 1′′ achromatic doublet, ARC: 650–1050 nm
Thorlabs AC254-100-A-ML L4 f = 100 mm, φ 1′′ achromatic doublet, ARC: 400–700 nm
Thorlabs AC254-100-A-ML L5 f = 100 mm, φ 1′′ achromatic doublet, ARC: 400–700 nm
Dichroic mirrors Semrock,
Rochester, NY, USA
FF685-Di02-25x36 DC1 Single-edge dichroic beamsplitter, edge wavelength:
685 nm long-pass, 25.2 mm × 35.6 mm × 1.1 mm
Semrock FF484-FDi01-25x36 DC2 Single-edge dichroic beamsplitter, edge wavelength:
484 nm long-pass, 25.2 mm × 35.6 mm × 1.1 mm
Filters Semrock FF01-640/40-25 F1 Single-band bandpass filter, centre wavelength: 640 nm,
bandwidth (FWHM): 48.9 nm, φ 25 mm
Semrock FF01-775/140-25 F2 Single-band bandpass filter, center wavelength: 775 nm,
bandwidth (FWHM): 146.3 nm, φ 25 mm
′′, inch; φ, diameter; ARC, anti-reflection coating; f, focal length; FWHM: full width at half-maximum; NA, numerical aperture.
Digital micro-mirror device
The mirrors on the digital micro-mirror device (DMD)
are arranged on a diamond pixel geometry (Fig. A3) with
a mirror pitch of 7.64μm and 10.8μm along the diagonal
and orthonormal directions, respectively (see also table
in Fig. A3E). Lines can be projected in three different
geometries ranging from thinnest when using every other
row (or column) over pixel-widthwhen using diagonals to
broadest when using each row (or column) (Fig. A3B). By
applying a tilt angle of β = 12 degrees, each micro-mirror
canbe switchedonor off individually (Fig. A3C). The relay
Mesoscope main specifications
max frame rate (loop-off) FR 1.6kHz
max field of view, camera space FOV 128px
pixel size p 6.5µm
optical magnification M ≈ FOV*p/d 0.0825
pixel size, object space p/M ~ 80µm
field of view, object space FOV/M 10.08mm
illumination intensity at sample ~ 1mW/mm2
Detection optics
objective, sample magnification M1 2x
effective focal length EFL1 100mm
tube lenses focal length f2 150mm
f3 150mm
objective, camera magnification M2 20x
effective focal length EFL2 8.25mm
10.1mm × 10.1mm
sample
camera
128px × 128px
80µm x 80µm
6.5µm x 6.5µm
M = M1 * M2 ≈ 0.0825 
L2 L3
M2=EFL2/f3M1=f2/EFL1 832µm × 832µm
f2 = 150mm f3 = 150mmf2 = 150mm f3 = 150mm WD2WD1
O1: 2x O2: 20x
A
B C
D O1 O2L3L4
BFP2 = 2*EFL2*NA3 = 6.6mmNA1,eff = BFP2 /(2*EFL1) = 0.033
Figure A2. Main considerations for the mesoscope’s temporal and spatial resolution
BFP, back focal plane diameter; NA, numerical aperture; O, objective; WD, working distance.
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optics used to project the DMD pattern onto the sample
(Fig. A3D) combine to a 1:1 re-imaging system by using
two identical objectives with two identical respective tube
lenses (Fig. A3F).When removing the projection lens from
the light crafter as described in Fig. 4, the DMD projects
a primary image of approximately 10 mm × 16 mm at
a distance d of 10 mm from the front housing of the
light crafter. Considering the active area of 6161.4 μm ×
9855 μm, the projection results in a 1.6 magnification.
The personal computer (PC) controlling the lightcrafter is
equipped with a graphics card that has two HDMI output
ports. One is used for the PC screen, and the other is used
to send activation patterns to the lightcrafter. See Table A2
for a full list of hardware components and Fig. A6 for
details of electronic connectivity.
Spatial resolution. Assuming a diagonal pixel line of
7.64μmwidth on theDMD, the resulting projected line in
the primary imaging plane has a width of 12.6 μm. Using
a wavelength of λ = 455 nm, unit magnification and an
NA of 0.1, the FWHMof the PSF of the re-imaging system
is PSF (FWHM) = 0.61 × λ × M/NA = 2.78 μm. This
means that the spatial resolution of the system is currently
limited by the micro-mirror size of the DMD.
Temporal resolution. The DMD can be operated in two
different modes, streaming and burst mode. In streaming
mode, the DMD receives continuous 24-bit patterns
from the parallel RGB interface and streams them at
2.88 kHz (data rate: 2.99 Gb s−1). In burst mode, 48
binary patterns are loaded from flash storage into inter-
nal memory and can be displayed at 4.22 kHz (data rate:
4.39 Gb s−1).
Optical efficiency. Averaging over different activation
patterns, the power coupling efficiency of the relay optics
Si
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DMD main specifications
micro-mirror pitch diag. p 7.64µm
along rows/columns p*srqrt(2) 10.8µm
row number h 912
column number w 1140
distance primary image* d 10mm
binary pattern burst rate 4.22kHz
24-bit pattern streaming rate 2.88kHz
illumination intensity at sample 4mW/mm2
DMD relay optics
objective1=3 magnification M1,3 2x
effective focal length EFL1,3 100mm
numerical aperture NA1,3 0.1
field of view FOV 11mm
tube lenses focal length F4 100mm
F5 100mm
every other row every row diagonally
Line thickness in diamond arrays
10.8µm 
10.8µ
m
 
micro-mirror tilt axis
DMD diamond pixel geometry
FOV: 11mm
sample
DMD
912px × 1140px
M = M1 * M3 = M12   = 1
L4 L5
M3=EFL3/f5M1=f4/EFL1
O3: 2xO1: 2x
projected
image plane
6161.4µm × 9855µm
10mm x 16mm
FOV: 11mm
x1.6
A B C
D
E F
f4 = 100mm f5 = 100mmf4 = 100mm f5 = 100mm WD3WD1 d=100mm
Figure A3. Specifications of the digital micro-mirror device (DMD) and its relay optics after removing
the projection lens
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was measured as 32.7 ± 0.8%. Using the LED driver at
the maximum permissible current (sum of all three LED
currents must be less than 4.3 A at all times), in the focal
plane of objective1 (sample plane) we obtain a maximum
intensity of 4 mWmm−2.
Modifications to the lightcrafter
In its native state, the RGB LEDs in the lightengine of
the lightcrafter (DLPLCR4500EVM, Texas Instruments)
are commanded by an internal LED driver that uses a
reduction of the duty cycle to dim light intensity. To
Projection lens
Jumper30
blue LED
green LED
Primary 
image
A B
C D
E F
Figure A4. The lightcrafter as optogenetic stimulation light source
A, remove the projection lens (yellow arrow) by gently wedging it out of its mount with a screwdriver. To bypass the
native LED driver, populate Jumper 30 (white arrow). Unplug the connectors (purple arrows) for the blue and green
LEDs (cyan arrows). B–D, using spacers (orange arrows, B) mount an aluminium plate with adequately spaced and
threaded through holes (C) to mount the external LED driver (D). E, on the LED driver, mount connectors for the
blue and green LED and connect them to the LED+ and LED− terminals (white arrows) in a series configuration
and solder a pull-up resistor (blue arrowhead). F, the lightcrafter is mounted on a manual xyz tip stage which is
approximately inclined by 10 degrees. Without the projection lens, the lightcrafter projects a primary image (white
arrow) approximately 10 mm from the front housing.
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Table A2. Hardware components
Component Manufacturer Part no. Specifications
LED Thorlabs, Newton, NJ,
USA
M625L3 625 nm centre wavelength, 18 nm FWHM
bandwidth, 700 mW, 1000 mA
Objectives Thorlabs TL2x-SAP ×2, 0.1 NA, 56.3 mm WD, 100 mm EFL (sample
and light crafter)
Zeiss, Oberkochen,
Germany
421350-9970-000 ×20, 0.4 NA, 7.9 mm WD, 8.25 mm EFL, coverslip
correction for 0.75 mm (camera)
Camera Hamamatsu Photonics,
Shizuoka, Japan
OrcaFlash4.0 v2.0 sCMOS sensor, 2048 × 2048, pixel size: 6.5 μm,
16-bit images
Lightcrafter Texas Instruments, Dallas,
TX, USA
DLPLCR4500EVM 912 × 1140 diamond pixel 0.45 inch WXGA
DMD, RGB LED light engine, two configurable
I/O triggers, video display up to WXGA
resolution (1280 × 800)
LED driver board Texas Instruments LM3433SQ- 4AEV/NOPB 9–14 V, 20 A
DAQ boards National Instruments NI USB-6212 AI: 400 kS s−1 multichannel; 16-bit resolution;
AO: 250 kS s−1, 16-bit resolution; 24 digital I/O
lines; two counters, 32-bit; 80 MHz max
counter frequency
NI USB 6002 AI: 50 kS s−1 multichannel; 16-bit resolution;
AO: 5 kS s−1, 16-bit resolution; 13 digital I/O
lines; one counter, 32-bit; 5 MHz max counter
frequency
Workstation Dell Precision Tower 5810 32 GB RAM, Intel Xeon processor E5-1630 v3 at
3.70 GHz, OS Windows 7 Professional 64-bit
Graphics card Nvidia, USA Quadro K620 2 GB DDR3 GPU memory, 128-bit memory
interface, 29 GB s−1 memory bandwidth, PCI
Express 2.0 × 16 interface, DVI-D DL + DP 1.2
display connectors
El. stimulator Digitimer, UK DS2A-Mk II 99 V output, low noise battery power supply,
int. (20 μs to 2 s) or ext. TTL control of pulse
duration
ECG ampliier A-M Systems Inc., USA 3000 AC/DC differential
amplifier
Noise: 1.8 μV, p-p (10 Hz to 10 kHz); 0.1 fA Hz−1
at 1 kHz; input impedance: 1015 Ohms/1 pF;
initial bias current: ±1.0 fA
Power supplies MeanWell, Taiwan T-60B For lightcrafter, 12 V output voltage, 5 A output
current, 60 W output power
RS components, UK RS-150-12 For external LED driver board; 12 V output
voltage, 12.5 A output current, 150 W output
power
Mechanical stages Thorlabs MLJ150-M motorized z-stage
MT-FN1 manual xy-stage
DMD, digital micro-mirror device; DVI, digital visual interface; EFL, effective focal length; FWHM, full width at half-maximum; GPU,
graphics processing unit; I/O, input/output; LED, light emitting diode; NA, numerical aperture; PCI, peripheral component interconnect;
RAM, random access memory; RGB, red green blue; SCMOS, scientific complementary metal-oxide semiconductor; TTL, transistor
transistor logic; WD, working distance.
circumvent dimming unsuitable for ChR2 excitation, an
external LED driver board (LM3433SQ-14AEV/NOPB)
was implemented into the lightcrafter. A complete list of
hardware components can be found in Table A2.
In the following, the procedure to adapt the lightcrafter
for use as an optogenetic stimulation source and to change
the LED driver board is described (see Fig. 4). Firstly,
remove the projection lens (yellow arrow, Fig. 4A) by
gently wedging it out of its mount with a screwdriver.
Secondly, tobypass thenativeLEDdriver, populate jumper
J30 (white arrow, Fig. 4A), then proceed to disconnect the
supply connectors (purple arrows, Fig. 4A) for the blue
and green LEDs (cyan arrows, Fig. 4A). Due to the wide
emission spectra of the green LED, light intensity within
the ChR2 excitation spectrum was increased by taking
advantage of the green tail inside the ChR2 excitation
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Figure A5. Emission spectra of the red green and blue LEDs in
the light engine
Spectrum is indicative only. Also shown is the transmission curve of
the dichroic filter (black) used for injecting the optogenetic excitation
light into the mesoscope beam path and the excitation spectrum of
ChR2 (cyan).
spectrum (see also Fig. A5, this document). By using
appropriate spacers (orange arrows, Fig. 4B andC) and an
aluminium plate, thirdly, mount the external LED driver
board on top of the lightcrafter.
The following modifications need to be made to the
LED driver board. First, solder new supply connectors for
the blue and green LEDs by connecting the cathode of
LED1 to the LED− pin, the anode of LED1 to the cathode
of LED2 and the anode of LED2 to the LED+ pin on the
external LED driver board. Second, solder the cables to
connect the LEDs and the driver board to external power
supplies. A pull-up resistor (blue arrows, Fig. 4D and E)
was used to ensure a well-defined off-state when the driver
was uncoupled. Mount the lightcrafter on a manual xyz
stage with additional tip movement since an inclination
of 10 degrees away from the optical axis is needed to
compensate for the intrinsic upwards projection of the
lightcrafter. Without the projection lens, the lightcrafter
projects an image at a distance of 15 mm. This image
(approx. 10 mm × 16 mm) was aligned to coincide with
the detection field of view of the objective (Fig. 4F).
Spectra of the light engine
Figure 5 shows the emission spectra of the three LEDs
in the light engine of the lightcrafter. Luminosity within
the excitation spectrum of ChR2 (cyan) was increased by
using not only the blue LED but also taking advantage
of the green tail peaking at approximately 425 nm with a
FWHMof approximately 25 nm. All spectra are indicative
only.Also shown is the relative transmissionof thedichroic
long-pass filter (black, FF484-FDi01, Semrock) used to
inject the optogenetic excitation light into the mesoscope
beam path. Table A3 lists the LED emission peak wave-
length and the spectrum bandwidth (FWHM).
Electronic connectivity scheme
As shown in Fig. A6, the mesoscope is operated via
two data acquisition devices (DAQ1: NI USB-6212 and
DAQ2: NI USB 6002, National Instruments), which are
Figure A6. Connectivity scheme of the mesoscope
DAQ, data acquisition device; ECG, electrocardiogram; ext, external; HDMI, high-definition multimedia interface;
I/O, input/output; LED, light emitting diode; USB, universial serial bus; PC, personal computer.
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Table A3. LED parameters
LED Centre (nm) Bandwidth (nm)
Blue 455 27
Green 520 100
Red 624 18
both connected to a PC via universal serial bus (USB).
DAQ1 provides an analog output (AO), which regulates
the current in the light emitting diode (LED) driver and
therefore LED emission power. Further, DAQ1 receives an
analog input (AI) from the ECG. A digital output (DO)
from DAQ1 provides an external trigger to the camera
and a programmable free interface (PFI) is used to trigger
the stimulator. DAQ2 supplies two outputs to the external
LED driver board mounted on the lightcrafter: an analog
channel supplies the current and thereforemodulates LED
emission power in the light engine while a digital channel
acts as a shutter. The camera is connected via a camera
link to an internal card inside the PC. The lightcrafter
is commanded via HDMI from the graphics card inside
the PC. See Table A2 for a complete list of hardware
components and their technical specifications.
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